Discover articles related to obesity
High demand and limited coverage have pushed some to gray-market GLP-1s. Learn the risks, legal context, safer access routes, and cost strategies.
Preliminary data suggest GLP-1 RAs may alter alcohol’s physiological and perceptual effects in people with obesity. What to know and discuss with your clinician.
Observational analyses suggest lower risk of certain cancers with GLP-1 therapy compared with insulin in type 2 diabetes. Caveats and context.
Late-stage trials suggest tirzepatide can significantly improve obstructive sleep apnea metrics. How to identify candidates and measure benefit.
